Literature DB >> 3609067

Bioavailability of dihydroergosine in healthy volunteers.

P Cvelbar, J Culig, Z Kopitar, A Lenardic, J U Smerkolj, M Zorz.   

Abstract

Eight healthy volunteers received an oral dose of 10 mg and an intravenous dose of 0.75 mg of dihydroergosine. Plasma concentrations were measured by HPLC method, and some pharmacokinetic parameters were calculated. The biologic half-life in the elimination phase was 8.35 +/- 1.87 h after oral administration and 8.84 +/- 3.64 h after intravenous administration. In both cases of administration a secondary rise in plasma concentration of dihydroergosine was observed, which can be attributed to hepatic recycling. The calculated bioavailability of the drug was 9.80 +/- 2.8%.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609067     DOI: 10.1007/BF03189854

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  8 in total

Review 1.  Clinical pharmacokinetics of ergotamine, dihydroergotamine, ergotoxine, bromocriptine, methysergide, and lergotrile.

Authors:  J Kanto
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1983-03

2.  Plasma kinetics of dihydroergotoxin in rat by using a radioreceptor assay.

Authors:  M Palmi; G Segre
Journal:  Pharmacol Res Commun       Date:  1984-05

3.  Bioavailability of dihydroergotamine in man.

Authors:  P J Little; G L Jennings; H Skews; A Bobik
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 4.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

5.  Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension.

Authors:  A Bobik; G Jennings; H Skews; M Esler; A McLean
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

6.  Pharmacokinetics of dihydroergosine in rats after intravenous and oral administration.

Authors:  A Mrhar; Z Kopitar; F Kozjek; L Krusic; A Lenardic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

7.  Dihydroergotoxine kinetics in healthy men after intravenous and oral administration.

Authors:  B G Woodcock; W Loh; W D Habedank; N Rietbrock
Journal:  Clin Pharmacol Ther       Date:  1982-11       Impact factor: 6.875

8.  Hemodynamic effects of two ergot derivatives in the conscious spontaneously hypertensive rat.

Authors:  D Susić; N Djordjević; D Kentera
Journal:  Pharmacology       Date:  1984       Impact factor: 2.547

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.